Analyzing Aldeyra Therapeutics (NASDAQ:ALDX) & Orion OYJ (OTCMKTS:ORINY)

Orion OYJ (OTCMKTS:ORINY) and Aldeyra Therapeutics (NASDAQ:ALDX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Orion OYJ and Aldeyra Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orion OYJ	0	2	1	0	2.33
Aldeyra Therapeutics	1	2	1	0	2.00

Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 254.84%. Given Aldeyra Therapeutics’ higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Orion OYJ.

Volatility & Risk

Orion OYJ has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.

Institutional & Insider Ownership

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 9.6% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Orion OYJ and Aldeyra Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orion OYJ	$2.14 billion	5.02	$566.04 million	$2.18	17.43
Aldeyra Therapeutics	N/A	N/A	-$33.85 million	($0.46)	-3.37

Orion OYJ has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Orion OYJ, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Orion OYJ and Aldeyra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orion OYJ	27.14%	50.01%	29.82%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Summary

Orion OYJ beats Aldeyra Therapeutics on 8 of the 12 factors compared between the two stocks.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.